Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Gag-Based DNA Vaccines Against HIV

Posted Nov 20 2012 7:00pm

Description of Invention:
Novel DNA vaccine constructs against HIV that express highly conserved elements (CE) within the HIV Gag protein and elicit strong, cross-clade cellular and humoral responses. The DNA vaccine vectors were engineered to express CEs for protection against different clades of HIV and prevention of immunodominance, two issues associated with current HIV vaccine candidates.

In vivo studies of Rhesus macaques vaccinated with variants of these constructs expressing seven highly CEs covering >99 of all known Gag sequences elicited strong, cellular T-cell and humoral antibody immune responses. The Gag-specific antibody responses were high titer and cross-clade. Cross-clade protection is important given the sequence diversity of HIV as is the absence of immunodominant epitopes that generate antibodies which are not protective against HIV.

Applications:
HIV vaccines

Advantages:
Addresses two key hurdles faced by current HIV vaccines: sequence diversity of HIV and immunodominance.

Development Status:
  • Early-stage
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Inventors:
George N Pavlakis (NCI)
Barbara K Felber (NCI)
James Mullins (University of Washington)


Patent Status:
HHS, Reference No. E-132-2012/0
US, Application No. 61/606,265 filed 02 Mar 2012


Related Technologies:
PCT, Application No. PCT/US01/45624 filed 01 Nov 2001, Reference No. E-308-2000/0
US, Application No. 13/190,969 filed 01 Nov 2001, Reference No. E-308-2000/0


Patent family filed in the U.S., Canada, Australia, Europe, and Japan


For Licensing Information Please Contact:
Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: changke@mail.nih.gov
Phone: 301-435-5018
Fax: 301-402-0220


Ref No: 2503

Updated: 11/2012

Post a comment
Write a comment:

Related Searches